CRISPR Therapeutics AG (CRSP) Net Equity Issued and Repurchased (2016 - 2026)

CRISPR Therapeutics AG has disclosed Net Equity Issued and Repurchased across 10 years of filings, most recently posting -$722000.0 for Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased fell 108.48% year-over-year to -$722000.0; the TTM figure through Jun 2026 stood at $182.1 million (up 518.1% YoY), while the FY2025 annual figure was $398.1 million, up 32.39% from the prior year.
• Net Equity Issued and Repurchased came in at -$722000.0 for Q1 2026 at CRISPR Therapeutics AG, down from $111.5 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $280.7 million in Q1 2024 to a low of -$1.0 million in Q2 2024.
• Average Net Equity Issued and Repurchased over 5 years is $47.7 million, with a median of $8.5 million recorded in 2025.
• Year-over-year, Net Equity Issued and Repurchased surged 1087.74% in 2025 and slumped 108.48% in 2026.
• Over 5 years, Net Equity Issued and Repurchased stood at $970000.0 in 2022, then surged by 3273.3% to $32.7 million in 2023, then slumped by 54.28% to $15.0 million in 2024, then surged by 645.31% to $111.5 million in 2025, then plunged by 100.65% to -$722000.0 in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were -$722000.0 in Q1 2026, $111.5 million in Q4 2025, and $71.3 million in Q3 2025.